Oroxylin A Directly Targets SRC to Inhibit the PI3K/AKT Signaling Axis in Pancreatic Cancer: An Integrated Bioinformatics and Experimental Study
Biomolecules · 05.05.2026 · 16 (5) · 685
DOI: 10.3390/biom16050685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 05.05.2026. Verfasst von Jiajun Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases, Flavonoids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic Research Program of Jiangsu, Young Science and Technology Talents Lifting Project of the Jiangsu Association for Science and Technology.
Abstract (Originalsprache)
Oroxylin A (OA), a natural flavonoid, has demonstrated anticancer potential; nevertheless, its precise molecular targets and mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unclear. To address this gap, we integrated network pharmacology, transcriptomic analysis (GSE101448), and molecular docking, which identified SRC as a core therapeutic target of OA. OA exhibited a strong binding affinity to SRC (−9.0 kcal/mol), and molecular dynamics simulation confirmed stable complex formation (RMSD 0.26 ± 0.02 nm). Combined with functional assays, these findings identify SRC as a critical therapeutic target. Importantly, clinical analysis revealed that SRC was significantly upregulated in PDAC tissues, correlating with poor prognosis. Subsequently, in vitro experiments demonstrated that OA dose-dependently suppressed proliferation, induced G2/M cell cycle arrest and apoptosis, and inhibited migration and invasion in MIA PaCa-2 and PANC-1 cells. These effects were accompanied by downregulation of MMP2 and MMP9. Mechanistically, OA selectively inhibited phosphorylation of SRC (Tyr416), PI3K, and AKT (Ser473) without altering total protein levels, suggesting that the SRC/PI3K/AKT axis is a primary pathway mediating OA’s anticancer activity. Furthermore, in vivo treatment with OA significantly reduced tumor growth in a murine xenograft model without observable toxicity, as indicated by stable body weight, normal organ histology, and unaltered serum liver and kidney function markers. Immunohistochemical analysis further confirmed decreased Ki67 and p-SRC/p-AKT expression, alongside increased cleaved caspase-3, in OA-treated tumors. Collectively, these findings identify SRC as a direct target of OA and demonstrate that OA suppresses PDAC progression through the inhibition of the SRC/PI3K/AKT signaling pathway, thereby supporting its potential as a safe and effective therapeutic candidate for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Förderung
- National Natural Science Foundation of China
- Basic Research Program of Jiangsu
- Young Science and Technology Talents Lifting Project of the Jiangsu Association for Science and Technology
- Outstanding Young Scientist Fund of the Nanjing Health Science and Technology Development Program
- Excellent Young Scientists Fund Cultivation Project of the National Natural Science Foundation of Nanjing Drum Tower Hospital
- Nanjing Drum Tower Hospital, Affiliated Hospital of the Medical School, Nanjing University
Zitieren
APA
Zhang, J., Song, M., Liu, H., Zhang, Y., Zhang, Y., Guan, Z., Zhang, S., Wang, J., Zhang, S., & Lv, Y. (2026). Oroxylin A Directly Targets SRC to Inhibit the PI3K/AKT Signaling Axis in Pancreatic Cancer: An Integrated Bioinformatics and Experimental Study. Biomolecules, 16(5), 685. https://doi.org/10.3390/biom16050685
Vancouver
Zhang J, Song M, Liu H, Zhang Y, Zhang Y, Guan Z, et al. Oroxylin A Directly Targets SRC to Inhibit the PI3K/AKT Signaling Axis in Pancreatic Cancer: An Integrated Bioinformatics and Experimental Study. Biomolecules. 2026;16(5):685. doi:10.3390/biom16050685
BibTeX
@article{Zhang2026,
author = {Zhang, Jiajun and Song, Mengke and Liu, Huijuan and Zhang, Yixuan and Zhang, Yin and Guan, Zujiao and Zhang, Song and Wang, Jialun and Zhang, Shu and Lv, Ying},
title = {Oroxylin A Directly Targets SRC to Inhibit the PI3K/AKT Signaling Axis in Pancreatic Cancer: An Integrated Bioinformatics and Experimental Study},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {5},
pages = {685},
doi = {10.3390/biom16050685}
}
EUVIMED